Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 16/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761972 | 0.80 | FGFR1 (0.45) | HPGDNPSR1HTTFGFR1 | |
| SCHEMBL1761572 | 0.80 | FGFR1 (0.44) | HPGDALDH1A1FGFR1MAPK1 | |
| SCHEMBL1761618 | 0.79 | HPGD (0.44) | HPGDALDH1A1FGFR1 | |
| SCHEMBL1762234 | 0.77 | TP53 (0.47) | HPGDALDH1A1FGFR1 | |
| SCHEMBL1761802 | 0.75 | FGFR1 (0.58) | HPGDNPSR1HTTALDH1A1FGFR1 | |
| SCHEMBL1761898 | 0.75 | FGFR1 (0.43) | HPGDALDH1A1FGFR1MAPK1 | |
| SCHEMBL1761946 | 0.73 | GABRA1 (0.46) | HPGDALDH1A1FGFR1 | |
| SCHEMBL1761987 | 0.73 | TP53 (0.44) | HPGDALDH1A1FGFR1 | |
| SCHEMBL1762050 | 0.73 | FGFR1 (0.45) | HPGDNPSR1HTTALDH1A1FGFR1 | |
| SCHEMBL1762114 | 0.73 | GABRA1 (0.47) | HPGDALDH1A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | HPGD 1966/4885NPSR1 112/4885HTT 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.